VBC-108

N/A

Report date: 2025/07/08 10:29:29

First In Class

Base Information

Drug NameVBC-108

Drug Alias NameVBC-108

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-Cadherin-17Anti-CLDN18DNA topoisomerase I inhibitors

TargetsCadherin-17Claudin-18 splice variant 2DNA topoisomerase I

Therapy Area/IndicationsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesVelaVigo (Hong Kong) Ltd

China Registration ClassN/A

Develop Information

Active CompaniesVelaVigo (Hong Kong) Ltd

Inactive CompaniesN/A

Active IndicationsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A